TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States

Executive Summary

• TempraMed announced that over 275 U.S. physicians are recommending the VIVI Cap to patients via the FrontrowMD platform, marking a significant milestone in its commercialization strategy.
• The partnership with FrontrowMD provides a scalable, physician‑driven channel that reinforces the VIVI Cap as a standard‑of‑care adjunct for temperature‑sensitive medications.
• Management highlighted that clinical endorsement is expected to drive patient adoption at scale and support broader B2C demand generation across multiple therapeutic areas.

Key Details

• Physician Participation: More than 275 physicians across the United States are actively recommending the VIVI Cap through FrontrowMD.
• Platform Role: FrontrowMD serves as a trusted physician‑engagement and education platform, enabling clinicians to discover and recommend innovative healthcare solutions.
• Commercial Impact: The physician‑driven adoption model is intended to strengthen trust, compliance, and patient engagement, creating a scalable channel for sustained B2C demand generation.
• Strategic Positioning: TempraMed positions the VIVI Cap as a standard‑of‑care adjunct, reinforcing its role in protecting temperature‑sensitive medications beyond pharmacy and clinic settings.
• Launch Timeline: The FrontrowMD partnership was initially launched in December 2025 and is now expanding to broader physician networks.
• CEO Quote: Ron Nagar emphasized that “physician recommendations are the most powerful drivers of patient behavior” and view the partnership as clinical endorsement translating directly into patient adoption at scale.
• Physician Testimonial: Dr. Knotresha Stewart highlighted the cap’s ability to provide continuous protection without advance planning, citing real‑world temperature exposure scenarios.

Notable Quotes

“Physician recommendations are the most powerful drivers of patient behavior in healthcare,” said Ron Nagar, CEO of TempraMed.
“What stands out to me about the VIVI Cap is that it can provide continuous protection without requiring advance planning,” said Dr. Knotresha Stewart of River Valley Healthcare Associates.